Loading...
Loading...
ACRX| Name | Value |
|---|---|
| Revenues | 0.6M |
| Cost of Revenue | 0.9M |
| Gross Profit | -0.3M |
| Operating Expense | 8.4M |
| Operating I/L | 75.9M |
| Other Income/Expense | -5.2M |
| Interest Income | 0.5M |
| Pretax | 70.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 70.7M |
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company specializing in the development and commercialization of therapies for acute pain treatment. Its primary product candidate, DSUVIA and DZUVEO, is a 30 mcg sufentanil sublingual tablet designed for moderate-to-severe acute pain. The company also develops ZALVISO, a patient-controlled analgesia system for hospital patients, ARX-02 for cancer breakthrough pain, and 4ARX-03 for mild sedation and pain relief during procedures. Additionally, it is exploring Niyad, a regional anticoagulant, and LTX-608, a nafamostat formulation for antiviral treatment. AcelRx Pharmaceuticals, Inc. generates revenue through the development and commercialization of these pain management therapies.
